Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-15

Clinical Trial Update: Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sorafenib in metastatic or unresectable kidney cancer was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: University of Nebraska | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-02-15